4D Molecular Therapeutics Inc.
11/06/2025 | Press release | Distributed by Public on 11/06/2025 05:05
Business/Financial Results (Form 8-K)
| Item 2.02 |
Results of Operations and Financial Condition. |
As of September 30, 2025, 4D Molecular Therapeutics, Inc. (the "Company") estimates that it had approximately $372.2 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of its financial closing procedures, including the completion of management's reviews. Accordingly, the unaudited preliminary cash, cash equivalents and marketable securities balance set forth above reflects its preliminary estimate with respect to such information, based on information currently available to management, and may vary from its actual financial position as of September 30, 2025. Further, this preliminary estimate is not a comprehensive statement or estimate of its financial results or financial condition as of September 30, 2025.
| Item 8.01 |
Other Events. |
The contents of Item 2.02 above are also incorporated by reference into this Item 8.01.
On November 6, 2025, the Company announced positive interim 1.5-to 3.5-yeardata from the Phase 1/2 PRISM clinical trial evaluating 4D-150in patients with wet age-relatedmacular degeneration ("wet AMD").
Interim Data from PRISM (Best Available as of Data Cutoff August 22, 2025):
Patient Cohort Overview
| • |
Phase 2b (n=30, all patients reached year 1.5): |
| • |
Broad disease activity |
| • |
Phase 2b subgroup: Recently diagnosed (n=15): |
| • |
Broad disease activity diagnosed within 6 months of trial entry |
| • |
This subgroup is most comparable to the cohort in the Phase 3 4FRONT clinical trials |
| • |
Phase 1/2a (n=24, all patients have reached year 2): |
| • |
Severe, recalcitrant disease activity |
Maintained Visual Acuity and Sustained Control of Retinal Anatomy in All Cohorts
| • |
Consistent maintenance of visual acuity as measured by best corrected visual acuity through up to 2 years |
| • |
Consistent control of retinal anatomy (central subfield thickness as measured on optical coherence tomography), with fewer fluctuations through up to 2 years |
Treatment Burden Reduction: Sustained, Durable Disease Control with Fewer Anti-VEGF Injections Through Up to 2 Years
Patients maintained a consistent and clinically meaningful reduction in supplemental injections following 4D-150both in year 1 and in follow-upthrough year 1.5 (Phase 2b cohort) and Year 2 (Phase 1/2a cohort).
|
Treatment Burden Reduction Following 4D-150 (Mean Supplemental Injections vs. Comparator) |
||||
|
Cohorts: |
Through Year 1 |
Through Year 1.5 (Phase 2b) & Year 2 (Phase 1/2a) |
||
|
Phase 2b1 Subgroup: Recently Diagnosed (Phase 3 comparable) |
94% | 92% | ||
|
Phase 2b1: Broad |
83% | 82% | ||
|
Phase 1/2a2: Severe, Recalcitrant |
83% | 79% | ||
| 1 |
Compared to projected aflibercept 2mg Q8 weeks (Phase 3 comparator) |
| 2 |
Compared to mean injections in prior 12 months |
Durability Maintained Consistently Across 6-MonthIntervals Through Up to 2 Years
Patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-monthintervals following dosing with 4D-150,supporting durable disease control across all measured intervals through up to 2 years of follow-up.
|
Mean Supplemental Anti-VEGF Injections per Patient by |
||||||||||||||
|
Cohorts: |
0 to 6 Months Includes impact of 4D-150 & aflibercept loading dose(s)* |
6 - 12 Months |
12 - 18 Months |
18 - 24 Months |
||||||||||
|
Phase 2b Subgroup: Recently Diagnosed (Phase 3 comparable) |
0.1 | 0.2 | 0.4 | pending | ||||||||||
|
Phase 2b: Broad |
0.4 | 0.6 | 0.6 | pending | ||||||||||
|
Phase 1/2a: Severe, Recalcitrant |
0.5 | 1.3 | 1.2 | 1.2 | ||||||||||
| * |
Week -1 in Phase 1/2a, Week -1 & 4 in Phase 2b |
Consistent Dose Response on Treatment Burden Reduction Across All Cohorts Favors Phase 3 Dose (3E10 vg/eye) Compared to Lower Dose (1E10 vg/eye)
| • |
Phase 2b subgroup recently diagnosed (at 1.5 years): 92% vs. 77% |
| • |
Phase 2b (at 1.5 years): 82% vs. 73% |
| • |
Phase 1/2a (at 2 years): 79% vs. 69% |
Safety Data for Phase 3 Dose (3E10 vg/eye, n=71):
| • |
4D-150continues to be well tolerated: |
| • |
Safety Endpoint - intraocular inflammation: |
| • |
As previously reported, within approximately the first 6 months (28 weeks) post-4D-150dosing, 2.8% (2 of 71) of patients had 4D-150-related1+ (mild) intraocular inflammation (IOI) (SUN/NEI scales), which were transient 1+ vitreous cells noted at a single timepoint |
| • |
Following the first 28 weeks post-4D-150dosing, no new cases of inflammation with approximately 1.5 to more than 3.5 years of follow-upon all patients as of the data cutoff |
| • |
99% (70 of 71) completed steroid prophylaxis taper on schedule |
| • |
99% (70 of 71) remained completely off steroids |
| • |
No 4D-150-relatedhypotony, endophthalmitis, vasculitis, occlusive/non-occlusiveretinal vasculitis or choroidal effusions observed to date |
4D Molecular Therapeutics Inc. published this content on November 06, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 06, 2025 at 11:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]